<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428268</url>
  </required_header>
  <id_info>
    <org_study_id>IF20-00003</org_study_id>
    <nct_id>NCT04428268</nct_id>
  </id_info>
  <brief_title>Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia</brief_title>
  <official_title>Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design Phase 2, double blinded, single-center, 1:1 randomized clinical trial of&#xD;
      Chloroquine vs Chloroquine/losartan for the treatment of SARS-CoV-2 pneumonia in&#xD;
      non-critically ill subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Phase 2, blinded, single-center, 1: 1 randomized clinical trial for the&#xD;
      treatment of SARS-CoV-2 pneumonia in non-critically ill subjects. Two of the co-investigators&#xD;
      and the data analyst will remain blind to group allocation until after statistical analysis.&#xD;
&#xD;
      The groups will consist of subjects receiving in one arm PO Chloroquine 450mg every 12 hours&#xD;
      and in the other arm, in addition to chloroquine, PO Losartan 25mg every 24 hours. Study&#xD;
      drugs will be administered for a total of 10 days enterally.&#xD;
&#xD;
      Baseline demographics and clinical characteristics will be registered and periodically during&#xD;
      the study.&#xD;
&#xD;
      nasopharyngeal swabs will be taken every 48hrs during hospitalization to determine the&#xD;
      presences and viral load of SARS-CoV-2, and daily EKG for QT interval monitoring.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>investigator will not be aware of the treatments or outcomes until the end of the study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Determine all-cause mortality up to 28 days after randomization of Chloroquine Phosphate Compared to Chloroquine Phosphate plus Losartan in Non-Critically Ill Patients with SARS-CoV-2 Pneumonia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome assessment</measure>
    <time_frame>28 days</time_frame>
    <description>Compare the clinical outcome of Chloroquine Phosphate treatment vs Chloroquine Phosphate plus Losartan in the follow-up visit at the end of treatment. Acording to NIH and FDA definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the adverse events associated to chloroquine and chloroquine plus losartan at 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative SARS-CoV-2 test</measure>
    <time_frame>28 days</time_frame>
    <description>Time to negative Polymerase chain reaction (PCR) test from baseline: testing every 48hrs until a negative result</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive chloroquine phosphate 450 mg every 12 hours orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroquine plus losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Chloroquine phosphate 450mg orally every 12hrs plus Losartan 25mg orally every 12hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine Phosphate Tablets</intervention_name>
    <description>Orally administered</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_label>Chloroquine plus losartan</arm_group_label>
    <other_name>Losartan tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women ≥18 years.&#xD;
&#xD;
          2. Oral tolerance or access for enteral administration of medication.&#xD;
&#xD;
          3. PCR or IgM for SARS-CoV-2 positive.&#xD;
&#xD;
          4. Negative pregnancy test in case of a woman of reproductive age.&#xD;
&#xD;
          5. Signature of a document proving informed consent.&#xD;
&#xD;
          6. Hospital admission for SARS-CoV-2 pneumonia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New alteration of the state of alert that does not revert after interventions 60&#xD;
             minutes after hospital admission.&#xD;
&#xD;
          2. Mean Arterial Pressure (MAP) ≤ 65mmHg despite initial resuscitation on arrival at the&#xD;
             centre.&#xD;
&#xD;
          3. History of allergy to chloroquine, hydroxychloroquine, piperaquine or primaquine.&#xD;
&#xD;
          4. Known patient with hearing loss.&#xD;
&#xD;
          5. Received chloroquine or hydroxychloroquine in the last 3 months.&#xD;
&#xD;
          6. Patients with cirrhosis or elevation of aspartate transaminase (AST) or alanine&#xD;
             transaminase (ALT) greater than three times the upper normal limit.&#xD;
&#xD;
          7. Patients with calculated glomerular filtration rate by Modification of Diet in Renal&#xD;
             Disease study equation (MDRD) &lt; 30ml/min 1.73 m2.&#xD;
&#xD;
          8. Patients known to be deficient in 6-phosphate dehydrogenase&#xD;
&#xD;
          9. Patients known to have retinopathy or macular disease.&#xD;
&#xD;
         10. History of acute myocardial infarction in the last 6 months, unstable angina,&#xD;
             ventricular tachycardia, ventricular fibrillation or class III-IV heart failure&#xD;
             according to New York Heart Association.&#xD;
&#xD;
         11. Electrocardiogram QTc interval ≥ 480 ms.&#xD;
&#xD;
         12. Patients with hypomagnesemia or uncorrected hypokalemia.&#xD;
&#xD;
         13. Patients with a history of psychiatric illness.&#xD;
&#xD;
         14. Patients who are pregnant or nursing.&#xD;
&#xD;
         15. Patients taking quinolones, dextropropoxyphene, amiodarone, flecainide, cisapride,&#xD;
             domperidone, atazanavir or lopinavir.&#xD;
&#xD;
         16. Patients with acute pancreatitis.&#xD;
&#xD;
         17. Patients who the investigators deem unsuitable for participation in the clinical&#xD;
             trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Camacho Ortiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario &quot;Dr. Jose Eleuterio Gonzalez&quot;, UANL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Pérez Alba, MD</last_name>
    <phone>+52 8117998705</phone>
    <email>md.eduardo.perez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Marina Nuzzolo Shihadeh, MD</last_name>
    <phone>+52 8112773423</phone>
    <email>laura.nuzzolo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario José E. Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Camacho, PhD</last_name>
      <phone>044 81 1263 5696</phone>
      <email>acamacho_md@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Pérez Alba, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Marina Nuzzolo Shihadeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrian Camacho-Ortiz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Diego Lecona García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dr. Adrian Camacho-Ortiz</investigator_full_name>
    <investigator_title>Head of the Infectious Disease Department</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 pneumonia</keyword>
  <keyword>Chloroquine phosphate</keyword>
  <keyword>Losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

